Phase 2 Hypertension Trial, Recruiting NCT07222917 Sponsor: AstraZeneca Condition: Hypertension
Back to Hypertension

Phase 2 Hypertension Trial, Recruiting

NCT07222917
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older at the time of signing the consent form
  • People whose kidneys are working at a reduced but not severely low level, based on a specific kidney function test result (eGFR between 30 and 90) at screening
  • People with a certain level of protein in their urine, within a specific range, at screening (confirm with trial site for exact values)
  • People with a history of high blood pressure, with blood pressure readings above certain levels at both the screening visit and the randomisation visit
  • People who have been taking a stable, maximum tolerated dose of one specific type of blood pressure medication (either an ACE inhibitor or an ARB, but not both) for at least 4 weeks before screening — unless this is not medically appropriate for them
  • People whose blood potassium level falls within a specific healthy range at screening, with the exact range depending on their kidney function result
  • Female participants whose use of contraception is consistent with local regulations for people taking part in clinical studies

Who may not be able to join:

  • People with very high blood pressure readings at screening (systolic above 180 mmHg or diastolic above 110 mmHg)
  • People who have had a high blood potassium level (5.5 mmol/L or above) within the 3 months before screening
  • People with a low blood sodium level at the screening visit
  • People with Type 1 diabetes, or people with poorly controlled Type 2 diabetes (based on a blood sugar control test result) at screening
  • People with the most severe category of heart failure symptoms (classified as New York Heart Association Class IV) at screening
  • People who have taken certain medications that affect potassium levels — including some heart and kidney medications — within 4 weeks before screening (confirm with trial site for the full list)
  • People who have had a stroke, mini-stroke, heart attack, certain heart procedures or surgeries, or a hospital admission for worsening heart failure within the 3 months before joining the trial
  • People with severe liver disease (classified as Child-Pugh Class C) based on documented medical history
  • People with a documented history of adrenal insufficiency (a condition affecting the adrenal glands)
  • People who have been on dialysis for any reason within the 3 months before screening
  • People who have had an acute (sudden) kidney injury within the 3 months before screening
  • People currently taking certain medications that are not permitted during this trial (confirm with trial site for the full list)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
5 December 2025
Est. completion
24 May 2027

Where this trial is recruiting

🇦🇷 Argentina 🇧🇬 Bulgaria 🇨🇦 Canada 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇹🇭 Thailand Turkey (Türkiye) 🇺🇦 Ukraine 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov